Literature DB >> 1824981

Advantages of F(ab')2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice.

R Hirsch1, J A Bluestone, C V Bare, R E Gress.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1824981

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  8 in total

1.  Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2.

Authors:  M Better; S L Bernhard; S P Lei; D M Fishwild; J A Lane; S F Carroll; A H Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

2.  Inter-mouse strain differences in the in vivo anti-CD3 induced cytokine release.

Authors:  C Ferran; M Dy; K Sheehan; S Merite; R Schreiber; P Landais; G Grau; J Bluestone; J F Bach; L Chatenoud
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

3.  Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.

Authors:  M G Wing; T Moreau; J Greenwood; R M Smith; G Hale; J Isaacs; H Waldmann; P J Lachmann; A Compston
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

Review 4.  Treatment of type 1 diabetes with anti-T-cell agents: from T-cell depletion to T-cell regulation.

Authors:  Mariela Glandt; Kevan C Herold
Journal:  Curr Diab Rep       Date:  2004-08       Impact factor: 4.810

Review 5.  Immunomodulation of transplant rejection using monoclonal antibodies and soluble receptors.

Authors:  M L Alegre; D J Lenschow; J A Bluestone
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

6.  Characterization of a surrogate murine antibody to model anti-human CD3 therapies.

Authors:  Fabien Dépis; Eric Hatterer; Romain Ballet; Bruno Daubeuf; Laura Cons; Sophie Glatt; Walter Reith; Marie Kosco-Vilbois; Yann Dean
Journal:  MAbs       Date:  2013-04-18       Impact factor: 5.857

Review 7.  Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation?

Authors:  Kevan C Herold; Lesley Taylor
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 8.  Treatment of type 1 diabetes with anti-CD3 monoclonal antibody.

Authors:  Mariela Glandt; William Hagopian; Kevan C Herold
Journal:  Rev Endocr Metab Disord       Date:  2003-12       Impact factor: 9.306
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.